Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. more
Time Frame | PPBT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -13.6% | 0.31% | -1.26% |
1-Month Return | -6.7% | 0.6% | -4.16% |
3-Month Return | -11.71% | -9.44% | -0.46% |
6-Month Return | -52.39% | -5.15% | 3.58% |
1-Year Return | -72.81% | 0.33% | 22.47% |
3-Year Return | -95.54% | 4.53% | 25.13% |
5-Year Return | -97.77% | 35.98% | 77.7% |
10-Year Return | -99.43% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.00M | 1.00M | (320.00K) | (910.00K) | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-32,"profit":false},{"date":"2022-12-31","value":-91,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 80.00 | 235.00K | 231.00K | 201.00K | 196.00K | [{"date":"2019-12-31","value":0.03,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.3,"profit":true},{"date":"2022-12-31","value":85.53,"profit":true},{"date":"2023-12-31","value":83.4,"profit":true}] |
Gross Profit | 999.92K | 765.00K | (551.00K) | (1.11M) | (196.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":76.51,"profit":true},{"date":"2021-12-31","value":-55.1,"profit":false},{"date":"2022-12-31","value":-111.11,"profit":false},{"date":"2023-12-31","value":-19.6,"profit":false}] |
Gross Margin | 99.99% | 76.50% | 172.19% | 122.09% | (Infinity%) | [{"date":"2019-12-31","value":58.07,"profit":true},{"date":"2020-12-31","value":44.43,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.9,"profit":true},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 8.75M | 13.79M | 17.93M | 22.60M | (22.47M) | [{"date":"2019-12-31","value":38.72,"profit":true},{"date":"2020-12-31","value":61.03,"profit":true},{"date":"2021-12-31","value":79.34,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-99.4,"profit":false}] |
Operating Income | (7.16M) | 12.61M | (17.93M) | (22.60M) | 22.27M | [{"date":"2019-12-31","value":-32.13,"profit":false},{"date":"2020-12-31","value":56.63,"profit":true},{"date":"2021-12-31","value":-80.53,"profit":false},{"date":"2022-12-31","value":-101.49,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 1.33M | (15.27M) | 216.00K | (42.68M) | (43.95M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-1145.46,"profit":false},{"date":"2021-12-31","value":16.2,"profit":true},{"date":"2022-12-31","value":-3201.58,"profit":false},{"date":"2023-12-31","value":-3297.45,"profit":false}] |
Pre-Tax Income | (5.89M) | (28.07M) | (17.83M) | (21.76M) | (19.98M) | [{"date":"2019-12-31","value":-589300000,"profit":false},{"date":"2020-12-31","value":-2807400000,"profit":false},{"date":"2021-12-31","value":-1782600000,"profit":false},{"date":"2022-12-31","value":-2176000000,"profit":false},{"date":"2023-12-31","value":-1997700000,"profit":false}] |
Income Taxes | 216.00K | (15.67M) | 637.00K | (935.00K) | (97.00K) | [{"date":"2019-12-31","value":33.91,"profit":true},{"date":"2020-12-31","value":-2459.81,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-146.78,"profit":false},{"date":"2023-12-31","value":-15.23,"profit":false}] |
Income After Taxes | (6.11M) | (12.40M) | (18.46M) | (20.82M) | (19.88M) | [{"date":"2019-12-31","value":-610900000,"profit":false},{"date":"2020-12-31","value":-1240500000,"profit":false},{"date":"2021-12-31","value":-1846300000,"profit":false},{"date":"2022-12-31","value":-2082500000,"profit":false},{"date":"2023-12-31","value":-1988000000,"profit":false}] |
Income From Continuous Operations | (5.89M) | (28.07M) | (17.83M) | (21.76M) | (19.98M) | [{"date":"2019-12-31","value":-589300000,"profit":false},{"date":"2020-12-31","value":-2807400000,"profit":false},{"date":"2021-12-31","value":-1782600000,"profit":false},{"date":"2022-12-31","value":-2176000000,"profit":false},{"date":"2023-12-31","value":-1997700000,"profit":false}] |
Income From Discontinued Operations | (642.00K) | (642.00K) | (642.00K) | - | - | [{"date":"2019-12-31","value":-64200000,"profit":false},{"date":"2020-12-31","value":-64200000,"profit":false},{"date":"2021-12-31","value":-64200000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (6.11M) | (12.40M) | (18.46M) | (20.82M) | (19.88M) | [{"date":"2019-12-31","value":-610900000,"profit":false},{"date":"2020-12-31","value":-1240500000,"profit":false},{"date":"2021-12-31","value":-1846300000,"profit":false},{"date":"2022-12-31","value":-2082500000,"profit":false},{"date":"2023-12-31","value":-1988000000,"profit":false}] |
EPS (Diluted) | (0.49) | (0.07) | (0.42) | (1.21) | (0.93) | [{"date":"2019-12-31","value":-49,"profit":false},{"date":"2020-12-31","value":-7,"profit":false},{"date":"2021-12-31","value":-42,"profit":false},{"date":"2022-12-31","value":-120.99,"profit":false},{"date":"2023-12-31","value":-92.61,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PPBT | |
---|---|
Cash Ratio | 1.15 |
Current Ratio | 1.27 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PPBT | |
---|---|
ROA (LTM) | -29.25% |
ROE (LTM) | -44.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PPBT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.16 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.84 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PPBT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 58.08 |
P/B | 0.32 |
Price/FCF | NM |
EV/R | 33.08 |
EV/Ebitda | NM |
Purple Biotech (PPBT) share price today is $3.62
Yes, Indians can buy shares of Purple Biotech (PPBT) on Vested. To buy Purple Biotech from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PPBT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Purple Biotech (PPBT) via the Vested app. You can start investing in Purple Biotech (PPBT) with a minimum investment of $1.
You can invest in shares of Purple Biotech (PPBT) via Vested in three simple steps:
The 52-week high price of Purple Biotech (PPBT) is $20.6. The 52-week low price of Purple Biotech (PPBT) is $2.
The price-to-earnings (P/E) ratio of Purple Biotech (PPBT) is
The price-to-book (P/B) ratio of Purple Biotech (PPBT) is 0.32
The dividend yield of Purple Biotech (PPBT) is 0.00%
The market capitalization of Purple Biotech (PPBT) is $9.35M
The stock symbol (or ticker) of Purple Biotech is PPBT